-+ 0.00%
-+ 0.00%
-+ 0.00%

Palatin targets first human studies of obesity drug PL2001 in first half of 2027

PUBT·11/16/2026 12:37:08
Diffusion vocale
Palatin targets first human studies of obesity drug PL2001 in first half of 2027
  • Palatin Technologies presented preclinical results at ObesityWeek 2026 showing its MC4R agonists reduced body weight and food intake in obese mice.
  • Receptor selectivity findings support the potential to reduce or eliminate hyperpigmentation associated with existing MC4R therapies.
  • Long-acting peptides showed extended drug exposure, supporting potential once-weekly or less frequent injections compared with currently approved daily therapy.
  • Lead candidate PL2001 targets first-in-human studies in the first half of 2027, with initial clinical data expected in the second half.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palatin Technologies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH97784) on November 16, 2026, and is solely responsible for the information contained therein.